HOOKIPA PHARMA INC (HOOK) Stock Price & Overview
NASDAQ:HOOK • US43906K2096
Current stock price
The current stock price of HOOK is 0.8403 USD. Today HOOK is down by -6.92%. In the past month the price decreased by -31.68%. In the past year, price decreased by -82.12%.
HOOK Key Statistics
- Market Cap
- 10.252M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.84
- Dividend Yield
- N/A
HOOK Stock Performance
HOOK Stock Chart
HOOK Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HOOK. When comparing the yearly performance of all stocks, HOOK is a bad performer in the overall market: 98.25% of all stocks are doing better.
HOOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HOOK. HOOK has a great financial health rating, but its profitability evaluates not so good.
HOOK Earnings
On August 6, 2025 HOOK reported an EPS of -1.23 and a revenue of 2.00M. The company missed EPS expectations (-15.95% surprise) and missed revenue expectations (-41.79% surprise).
HOOK Forecast & Estimates
7 analysts have analysed HOOK and the average price target is 29.07 USD. This implies a price increase of 3359.48% is expected in the next year compared to the current price of 0.8403.
For the next year, analysts expect an EPS growth of 24.44% and a revenue growth -49.08% for HOOK
HOOK Groups
Sector & Classification
HOOK Financial Highlights
Over the last trailing twelve months HOOK reported a non-GAAP Earnings per Share(EPS) of -5.84. The EPS decreased by -16.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.68% | ||
| ROE | -215.12% | ||
| Debt/Equity | 0 |
HOOK Ownership
HOOK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 366.329B | ||
| AMGN | AMGEN INC | 15.51 | 190.793B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 171.639B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 115.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.234B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.05 | 43.592B | ||
| INSM | INSMED INC | N/A | 31.968B | ||
| NTRA | NATERA INC | N/A | 27.973B | ||
| BIIB | BIOGEN INC | 11.77 | 27.764B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.13 | 23.738B | ||
| MRNA | MODERNA INC | N/A | 21.145B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.686B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HOOK
Company Profile
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Company Info
IPO: 2019-04-18
HOOKIPA PHARMA INC
350 Fifth Avenue, 72Nd Floor, Suite 7240
New York City NEW YORK 10118 US
CEO: Joern Aldag
Employees: 82
Phone: 114318906360
HOOKIPA PHARMA INC / HOOK FAQ
What does HOOKIPA PHARMA INC do?
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Can you provide the latest stock price for HOOKIPA PHARMA INC?
The current stock price of HOOK is 0.8403 USD. The price decreased by -6.92% in the last trading session.
What is the dividend status of HOOKIPA PHARMA INC?
HOOK does not pay a dividend.
What is the ChartMill rating of HOOKIPA PHARMA INC stock?
HOOK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of HOOK stock?
HOOKIPA PHARMA INC (HOOK) has a market capitalization of 10.25M USD. This makes HOOK a Nano Cap stock.
What is the next earnings date for HOOK stock?
HOOKIPA PHARMA INC (HOOK) will report earnings on 2025-11-12.
What is the Short Interest ratio of HOOKIPA PHARMA INC (HOOK) stock?
The outstanding short interest for HOOKIPA PHARMA INC (HOOK) is 0.28% of its float.